| You are here: Home: BCU 5|2004: Melody A Cobleigh, MD: Select publications
Select publications
Claus EB et al. Pathobiologic findings in DCIS of the breast: Morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 2001;70(3):303-16. Abstract
Cobleigh MA et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughput RT-PCR assay of paraffinembedded tumor tissues. Proc ASCO 2003;Abstract 3415.
Esteban J et al. Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue. Proc ASCO 2003;Abstract 3416.
Hoque A et al. HER-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2002;11(6):587-90. Abstract
Miller KD et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76(Suppl 1);Abstract 36.
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Paik S et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients — NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003;82(Suppl 1):10;Abstract 16.
Parton M et al. High incidence of HER2 positivity in inflammatory breast cancer. Breast 2004;13(2):97-103. Abstract
Tripathy D et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
